70基因检测与21基因检测中危早期乳腺癌医生治疗决策的关联
PROMIS研究纳入840例21基因检测复发评分18-30的早期乳腺癌患者,在辅助治疗前提供70基因签名检测结果。70基因检测低危374例(44.5%),高危466例(55.5%);282例(33.6%)的治疗决策发生改变,低危组108例(28.9%)删去化疗,高危组171例(36.7%)增加化疗;660例(78.6%)医生报告治疗推荐信心增加。
要点
- 21基因检测中危患者中,70基因检测可区分低危和高危,且分布与复发评分不相关。
- 70基因检测结果与医生辅助治疗决策改变相关(OR 0.64,95%CI 0.50-0.82;P<.001)。
- 低危组28.9%删去化疗,高危组36.7%增加化疗;78.6%医生报告信心增加。
核心结论
- 70基因签名检测为21基因检测中危患者提供可操作信息,与治疗决策改变相关(282/840,33.6%)。
- 医生根据70基因检测结果增加或省略化疗,并报告治疗推荐信心增加。
研究设计与样本
- PROMIS试验为影响研究,2012年5月20日至2015年12月31日纳入840例早期乳腺癌患者,21基因检测复发评分18-30,来自58家美国机构。
主要发现
- 70基因检测低危374例(44.5%),高危466例(55.5%);70基因指数分布与21基因中危范围内的复发评分不相关。
- 全部患者中,接受70基因分类与辅助治疗显著改变相关,OR 0.64(95%CI 0.50-0.82;McNemar检验,P<.001)。
- 低危组374例中108例(28.9%)从治疗推荐中删去化疗;高危组466例中171例(36.7%)增加化疗。
- 409例高危患者(87.8%)被推荐接受辅助化疗,339例低危患者(90.6%)被推荐不接受化疗。
- 660例(78.6%)医生报告基于70基因检测结果对治疗推荐信心增加。
关键数值与推荐
- 21基因检测中危定义为复发评分18-30。
- 70基因检测低危374例(44.5%),高危466例(55.5%)。
- 治疗改变大于20%时应用比值比(OR)。
- 全部患者治疗改变OR 0.64(95%CI 0.50-0.82;P<.001)。
临床怎么用
- 对21基因检测中危的早期乳腺癌患者,70基因检测结果与医生辅助治疗决策改变相关,医生可据此增加或省略化疗。
- 医生报告在获得70基因检测结果后对治疗推荐信心增加。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Among patients who undergo the 21-gene assay (21-GA), 39% to 67% receive an intermediate risk result and may receive ambiguous treatment guidance. The 70-gene signature assay (70-GS) may be associated with physicians' treatment decisions in this population with early breast cancer. OBJECTIVE: To determine whether 70-GS findings are associated with physicians' decisions about adjuvant treatment and confidence in their recommendations and to evaluate the dichotomous (high- vs low-risk) and continuous distribution of 70-GS indices among this group of patients with intermediate risk. DESIGN, SETTING, AND PARTICIPANTS: The Prospective Study of MammaPrint in Breast Cancer Patients With an Intermediate Recurrence Score (PROMIS trial) was an impact study conducted from May 20, 2012, through December 31, 2015, that enrolled 840 patients with early-stage breast cancer and a 21-gene assay recurrence score of 18 to 30. Patients were treated in 58 US institutions. INTERVENTIONS: The 70-GS result was given to physicians before adjuvant treatment. MAIN OUTCOMES AND MEASURES: Change in physician treatment decision before vs after receiving the 70-GS result. With a treatment change of greater than 20%, the odds ratio (OR) was applied. RESULTS: Among the 840 patients who underwent 70-GS classification (mean age, 59 years; range, 27-93 years), 374 (44.5%) had a low-risk and 466 (55.5%) had a high-risk result. The distribution of 70-GS indices did not correlate with recurrence score within the 21-GA intermediate range, with 70-GS low- and high-risk patients observed at every recurrence score. A significant change in adjuvant treatment was associated with receiving the 70-GS classifications with an OR of 0.64 (95% CI, 0.50-0.82; McNemar test, P < .001) for all patients. Among the low-risk patients, 108 of 374 (28.9%) had chemotherapy removed from their treatment recommendation; among the high-risk patients, 171 of 466 (36.7%) had chemotherapy added. Results of the 70-GS were associated with the physician's adjuvant treatment recommendation; 409 high-risk patients (87.8%) were recommended to receive adjuvant chemotherapy, and 339 low-risk patients (90.6%) were recommended no chemotherapy. Physicians reported having greater confidence in their treatment recommendation in 660 cases (78.6%) based on 70-GS results. CONCLUSIONS AND RELEVANCE: The 70-GS provides clinically actionable information regarding patients classified as intermediate risk by the 21-GA and was associated with a change in treatment decision in 282 of these patients (33.6%). Chemotherapy was added or withheld by the treating physician based on the results of the 70-GS test. Physicians reported more confidence with their treatment recommendation after receiving 70-GS results.
引用
- Tsai M, Lo S, Audeh W, et al. Association of 70-Gene Signature Assay Findings With Physicians' Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay. JAMA Oncol. 2018. PMID: 29075751. doi:10.1001/jamaoncol.2017.3470
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。